(2S)-2-[(2,4-dimethoxybenzyl)amino]butan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-[(2,4-dimethoxybenzyl)amino]butan-1-ol
• 英文别名: (2S)-2-[(2,4-dimethoxyphenyl)methylamino]butan-1-ol
• 化学式: C₁₃H₂₁NO₃
• 分子量: 239.315
• InChiKey: BSVRULRQUWFQLQ-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  50.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Pyridine compounds
  申请人：Daiichi Sankyo Company, Limited

  公开号：US10221195B2

  公开（公告）日：2019-03-05

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH═, —C(—R7)═, or —N═, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有优异的组织非特异性碱性磷酸酶抑制活性的化合物或其药理学上可接受的盐。本发明提供了一种由式（I）代表的化合物： 其中 R1 代表氢原子、任选取代的 C1-6 烷基或类似物，R2 和 R3 相同或不同，且各自代表氢原子、任选取代的 C1-6 烷基或类似物，R4 和 R5 相同或不同，且各自代表氢原子、X代表-CH═、-C(-R7)═或-N═，m代表1至4，或其药理上可接受的盐。
• PYRIDO-OXAZINONE DERIVATIVES AS TNAP INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3319970B1

  公开（公告）日：2019-08-28
• PYRIDINE COMPOUNDS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20170210755A1

  公开（公告）日：2017-07-27

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R 1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R 2 and R 3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R 4 and R 5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R 6 represents a hydrogen atom or the like, each R 7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH═, —C(—R 7 )═, or —N═, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.
• US9879032B2
  申请人：——

  公开号：US9879032B2

  公开（公告）日：2018-01-30
• US9920068B2
  申请人：——

  公开号：US9920068B2

  公开（公告）日：2018-03-20